VIVUS, Inc. (VVUS)
(Delayed Data from NSDQ)
$3.73 USD
+0.03 (0.81%)
Updated May 3, 2019 04:13 PM ET
After-Market: $3.83 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$3.73 USD
+0.03 (0.81%)
Updated May 3, 2019 04:13 PM ET
After-Market: $3.83 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Rigel Pharmaceuticals' NDA for Tavalisse Accepted by FDA
by Zacks Equity Research
Rigel Pharmaceuticals, Inc. (RIGL) announced that the FDA has accepted its new drug application (NDA) seeking approval for its oral spleen tyrosine kinase inhibitor, fostamatinib for the treatment of patients with chronic and persistent immune thrombocytopenia
Amgen's Xgeva Myeloma Label Expansion sBLA Accepted by FDA
by Zacks Equity Research
Amgen Inc. (AMGN) announced that the FDA has accepted its supplemental Biologics License Application (sBLA) to expand the label of its key drug, Xgeva.
Merrimack Completes Enrollment in Phase II Study for MM-141
by Zacks Equity Research
Merrimack Pharmaceuticals announced completion of enrollment in the ongoing phase II study, evaluatingMM-141 in combination with standard of care for treatment of patients with previously untreated metastatic pancreatic cancer.
Seattle Genetics Halts Phase III Study on Leukemia Drug
by Zacks Equity Research
Seattle Genetics, Inc. (SGEN) announced that it will discontinue the phase III study, CASCADE o vadastuximab talirine (SGN-CD33A) in frontline older acute myeloid leukemia (AML) patients.
Fibrocell Science (FCSC) Looks Good: Stock Moves Up 13.9%
by Zacks Equity Research
Fibrocell Science, Inc. (FCSC) moved big last session, as its shares rose almost 14% on the day.
Celgene Presents Interim Results from Cancer Drug Study
by Zacks Equity Research
Celgene Corporation (CELG) announced encouraging results from an interim analysis of a phase IIIb study, MAGNIFY, on Revlimid.
Bristol-Myers Opdivo Positive in Phase II Study CheckMate-205
by Zacks Equity Research
Bristol-Myers Squibb Company (BMY) announced an extended follow-up data on immuno-oncology drug Opdivo.
GlaxoSmithKline's Benlysta Positive in Continuation Trial
by Zacks Equity Research
GlaxoSmithKline plc (GSK) announced positive results from a phase II continuation study evaluating the efficacy and safety of its marketed drug, Benlysta, in combination with standard of care for treatment systemic lupus erythematosus (SLE).
AveXis (AVXS) Surges: Stock Moves 5% Higher
by Zacks Equity Research
AveXis (AVXS) was a big mover last session, as the company saw its shares rise over 5% on the day.
Mallinckrodt Initiates Amyotrophic Lateral Sclerosis Study
by Zacks Equity Research
Mallinckrodt plc (MNK) announced that it has enrolled the first patient in its phase IIB study, PENNANT.
Omeros (OMER) Hits New 52-Week High on Positive FDA Decision
by Zacks Equity Research
Omeros Corporation (OMER) shares hit a new 52-week high of $22.80 on Thursday before eventually closing at $22.15.
Epizyme (EPZM) Jumps: Stock Rises 17.4%
by Zacks Equity Research
Epizyme (EPZM) was a big mover last session, as the company saw its shares rise over 17% on the day.
Selecta Biosciences (SELB) In Focus: Stock Moves 6.5% Higher
by Zacks Equity Research
Selecta Biosciences (SELB) moved big last session, as its shares jumped over 6% on the day.
NantKwest (NK) Looks Good: Stock Moves Up 8.5% in Session
by Zacks Equity Research
NantKwest, Inc. (NK) moved big last session, as its shares rose over 8% on the day.
Celgene (CELG) Reports Data on Lupus Drug in Phase II Trial
by Zacks Equity Research
Celgene Corporation (CELG) announced results from the phase II trial, SLE-001 which evaluated lupus candidate, CC-220, at the Annual European Congress of Rheumatology (EULAR) 2017 in Madrid.
Novartis (NVS) Announced Positive Data on Psoriasis Cosentyx
by Zacks Equity Research
Novartis AG (NVS) announced positive data on arthritis drug Cosentyx from two phase III studies.
Acceleron (XLRN) Kidney Cancer Candidate Fails in Phase II
by Zacks Equity Research
Acceleron Pharma Inc.'s (XLRN) announced disappointing results from a phase II study evaluating its pipeline candidate dalantercept in combination with Pfizer's (PFE) Inlyta (axitinib) for treatment of advanced renal cell carcinoma (RCC).
Omeros (OMER) Lead Candidate Gets Breakthrough Designation
by Zacks Equity Research
Omeros Corporation (OMER) announced that the FDA granted breakthrough therapy designation to pipeline candidate OMS721.
Novo Nordisk (NVO) Presents Data for Type II Diabetes Drug
by Zacks Equity Research
Novo Nordisk (NVO) announced positive results from the post-hoc analysis of the cardiovascular outcomes study, LEADER on Victoza.
Exelixis Initiates Cabozantinib-Tecentriq Combination Trial
by Zacks Equity Research
Exelixis, Inc. (EXEL) announced that it initiated the dose-escalation stage of a phase Ib trial of cabozantinib in combination with Roche's (RHHBY) Tecentriq.
Gilead (GILD) Submits NDA for HIV Combination Therapy Regimen
by Zacks Equity Research
Gilead Sciences, Inc. (GILD) announced that it has submitted a NDA to the FDA for an investigational HIV combination therapy regimen.
Seres Therapeutics' Stock Up as SER-109 Moves to Phase III
by Zacks Equity Research
Shares of Seres Therapeutics, Inc. (MCRB) went up by more than 5% on Monday, after it announced that its lead pipeline candidate, SER-109, has moved into late-stage development for the treatment of multiply recurrent C. difficile infection.
GTx's (GTXI) Enobosarm Positive in Phase II Study; Shares Up
by Zacks Equity Research
GTx, Inc.'s (GTXI) shares have climbed almost 99% after the company announced positive data from a phase II study, evaluating enobosarm for treating postmenopausal women with stress urinary incontinence.
Intercept (ICPT) Releases Data from Phase II Flint Trial
by Zacks Equity Research
Intercept Pharmaceuticals, Inc. (ICPT) announced a retrospective analysis of the phase II trial, FLINT, in patients who were diagnosed with nonalcoholic steatohepatitis (NASH) and type II diabetes.
Amgen's Multiple Myeloma Drug Receives NICE Recommendation
by Zacks Equity Research
Amgen Inc. (AMGN) announced that Kyprolis gained recommendation from National Institute for Health and Care Excellence (NICE) in combination with dexamethasone for the treatment of relapsed multiple myeloma.